๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

O23 Proliferation and apoptosis in multiple myeloma prognostic factors or kinetic parameters?

โœ Scribed by J. Minarik; V. Scudla; M. Ordeltova; J. Bacovsky; M. Zemanova; T. Pika


Book ID
104323055
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
47 KB
Volume
21
Category
Article
ISSN
0268-960X

No coin nor oath required. For personal study only.

โœฆ Synopsis


note, in 19 patients, remission achieved by bortezomib-based therapy was consolidated by high-dose therapy followed by autologous stem cell transplantation. With a median follow-up time of 11 months (1 27 months), the median progression-free survival of our entire patient population is 13.8 month, while the median overall survival has not been reached yet. We conclude that in a real-life setting, such as the entire myeloma practice of our Department, impressive medium-term survival results may be achieved using bortezomib-based therapy.


๐Ÿ“œ SIMILAR VOLUMES


O58 Correlation between chromosomal aber
โœ H. Greslikova; P. Kuglik; H. Filkova; A. Oltova; Z. Adam; A. Krivanova; L. Pour; ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 44 KB

Six pts had progressive disease, two pts died in infections (1. Candida tropicalis pneumonia caused fatal pulmonary bleeding on day +8; 2. in another case a multiorgan failure developed after Enterococcus sepsis on day +115). Follow up time is 28 months (1 78), 12/17 pts are in complete remission (C